BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed TGTX catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:d5f42d6fa4ccaeced35d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:TGTX P3 readout (est.): ENHANCE
DESCRIPTION:Study to Evaluate Safety\, Efficacy and Pharmacokinetics (PK) o
 f a Modified Regimen of Ublituximab\nNCT05877963 | PHASE3 | RECRUITING | s
 ponsor: TG Therapeutics\, Inc.\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nTicker TGTX (confidence 0.9)\nSource: 
 https://clinicaltrials.gov/study/NCT05877963\nScheduling/reference data fr
 om public records\; dates can move. Not investment\, legal or medical advi
 ce.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05877963
CATEGORIES:readout,ESTIMATED
END:VEVENT
END:VCALENDAR
